1.01

4.72% -0.05

Pre-market: 1.01

Xilio Therapeutics Inc (XLO)

Overview News Price History Discussions Forecast

Xilio Therapeutics Inc stock is currently priced at $1.01, with a 24-hour trading volume of 239.35K. It has seen a -4.72% decreased in the last 24 hours and a +44.31% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.06 pivot point. If it approaches the $1.01 support level, significant changes may occur.

Previous Close:

$1.06

Open:

$1.06

24h Volume:

239.35K

Market Cap:

$37.28M

Revenue:

Net Income/Loss:

$-81.22M

P/E Ratio:

-0.329

EPS:

-3.07

Net Cash Flow:

$-74.41M

1W Performance:

-21.09%

1M Performance:

+44.31%

6M Performance:

-48.99%

1Y Performance:

-68.83%

1D Range:

$0.951

$1.08

52W Range:

$0.49

$3.40

Xilio Therapeutics Inc Stock (XLO) Company Profile

Name

Xilio Therapeutics Inc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

617-430-4680

Address

828 Winter Street, Waltham

Employee

Twitter

Next Earnings Date

Latest SEC Filings

XLO's Discussions on Twitter

Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-21-22	Initiated	Chardan Capital Markets	Buy
Jan-10-22	Initiated	H.C. Wainwright	Buy
Nov-16-21	Initiated	Cowen	Outperform
Nov-16-21	Initiated	Guggenheim	Buy
Nov-16-21	Initiated	Morgan Stanley	Overweight
Nov-16-21	Initiated	Raymond James	Outperform

View All

Xilio Therapeutics Inc Stock (XLO) Latest News

Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why

Zacks Investment Research

Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket

Benzinga

Sizing Your Penny Stocks Position, 3 Tips

PennyStocks

Crude Oil Surges Over 2%; MSC Industrial Shares Fall After Q2 Results

Benzinga

Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Gold Gains 1%; Walgreens Narrows Earnings Forecast

Benzinga

Xilio Therapeutics Inc Stock (XLO) Financials Data

Xilio Therapeutics Inc (XLO) Net Income 2024

XLO net income (TTM) was -$81.22 million for the quarter ending September 30, 2023, a +4.96% increase year-over-year.

Xilio Therapeutics Inc (XLO) Cash Flow 2024

XLO recorded a free cash flow (TTM) of -$74.41 million for the quarter ending September 30, 2023, a +2.60% increase year-over-year.

Xilio Therapeutics Inc (XLO) Earnings per Share 2024

XLO earnings per share (TTM) was -$2.96 for the quarter ending September 30, 2023, a +12.43% growth year-over-year.

Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.